Hearing the words “triple-negative breast cancer” (TNBC) can be overwhelming. It’s a diagnosis that sounds heavy — not just because breast cancer itself is frightening, but because this particular subtype has a reputation for being more aggressive and harder to treat.
Yet the landscape of TNBC treatment has changed dramatically with major advances in recent years, giving us new hope. To help make sense of this complex diagnosis, I’m sharing what I see every day in my practice, what our community at Breastcancer.org is experiencing, and what the latest science is telling us.
What is triple-negative breast cancer?
Breast cancer is defined, in part, by three key protein receptors: estrogen (ER), progesterone (PR), and HER2. When a tumor has any of these receptors, it allows doctors to aim at a clear target with specific therapies, like hormone-blocking drugs for hormone receptor-positive cancers, or anti-HER2-targeted medications.
Triple-negative breast cancer is called “triple-negative” because the tumor lacks all three of these receptors. That absence is exactly what makes it more challenging to treat: These targeted forms of treatment don’t work. Instead, new treatments against new targets have to be used.
TNBC is a form of invasive breast cancer, meaning it has broken out of the milk ducts or lobules from where it started. It also tends to grow faster than hormone receptor-positive breast cancers, which is why early detection is especially critical. No matter what your pathology report says, there are many effective treatments. And researchers are also working to develop new options and figure out how to better tailor treatments to each person’s unique diagnosis and situation.
What are the risk factors for triple-negative breast cancer?
TNBC accounts for about 10 to 15 percent of all breast cancer cases — which, given that an estimated 321,910 new cases of invasive breast cancer will be diagnosed in the U.S. in 2026, means tens of thousands of people will receive this diagnosis this year.
Importantly, TNBC does not affect all populations equally. More Black women are diagnosed with triple negative breast cancer at young ages — in the prime of their lives, when so much is at stake. Black women are diagnosed with TNBC at approximately twice the rate of white women: About 20 percent of breast cancer cases in Black women are triple-negative, compared to roughly 10 percent in the general population.
For them, it’s especially important to get the best care possible, starting with an accurate diagnosis, inherited genetic testing, and access to a combination of newer forms of treatments on clinical trials or based on the results of published studies.
People younger than 40 and those with a BRCA1 genetic mutation are also at higher risk for this subtype. The average age at diagnosis for TNBC is around 53 to 54, notably younger than the overall average age of 62 for breast cancer.
How do physicians screen for triple-negative breast cancer?
There is no specific test. Instead, TNBC is typically detected using standard breast cancer detection tools, which is why keeping up with those screenings is crucial.
Mammography remains the cornerstone of early detection, and the American Cancer Society recommends that women at average risk begin annual mammograms at age 45, with the option to start at 40. For women at higher risk — including those with a BRCA1 mutation, a strong family history of breast cancer, or dense breast tissue — supplemental MRI screening may be recommended in addition to mammography. Breast MRI is more sensitive and can be especially valuable for catching TNBC early, before it spreads.
Genetic testing is also critically important. Every person diagnosed with TNBC — regardless of age or stage — should get genetic testing. It’s now the standard of care. About 10 to 15 percent of TNBC patients will be found to carry a BRCA mutation, and that information directly shapes treatment decisions.
How is triple-negative breast cancer treated?
Treatment for TNBC is highly individualized and depends on the stage of the cancer and its specific characteristics. The standard approach typically involves some combination of the following:
- Surgery: Depending on the tumor’s size and location, doctors may recommend a mastectomy or lumpectomy to remove the cancer.
- Radiation therapy: It’s common to have radiation therapy after a lumpectomy. A doctor may or may not recommend radiation after a mastectomy, depending on the characteristics of the cancer.
- Chemotherapy: Chemotherapy is the backbone of treatment. It may be given before surgery (neoadjuvant) to shrink the tumor, or after surgery (adjuvant) to reduce the risk of recurrence. It uses one or more medicines to slow or stop the growth of cancer cells. (TNBC doesn’t respond to hormone therapy or HER2-targeted drugs.)
- Targeted therapies: For metastatic TNBC, patients may receive treatments targeted at specific characteristics of the tumor.
- Immunotherapy (Keytruda/pembrolizumab): Immunotherapy medicines stimulate the body’s immune system to attack cancer cells. They're now part of standard treatment for high-risk early-stage TNBC, and for metastatic TNBC, especially when it tests positive for a protein called PD-L1.
- PARP inhibitors: For patients with BRCA1, BRCA2 or PALB2 mutations, PARP inhibitors (such as olaparib or talazoparib) are targeted drugs that block cancer cells’ ability to repair their own DNA, essentially stopping them in their tracks.
Five-year relative survival rates for TNBC vary significantly by stage: 92.4 percent for localized disease, 67.4 percent for regional spread (when it involves lymph nodes), and 14.9 percent for distant (metastatic) disease — which underscores why catching it early makes such a difference.
New treatments for triple-negative breast cancer
Research on TNBC is currently one of the most exciting areas in oncology. Scientists now recognize that TNBC is not one disease, but a collection of related diseases with distinct biological profiles — and different potential vulnerabilities — leading to different forms of effective therapies.
Antibody-drug conjugates (ADCs) — sometimes called “smart chemo” — are one of the most promising new drug classes. These are engineered molecules that deliver chemotherapy directly and precisely to cancer cells, reducing side effects to healthy tissue. Trodelvy (sacituzumab govitecan), which targets a protein called Trop-2 found in about 80 percent of breast cancers, is already approved for metastatic TNBC. Researchers are also finding that even TNBC tumors that were previously considered HER2-negative may have very low levels of HER2 expression — and new ADCs that include anti-HER2 treatments may be effective even in those patients.
Tumor-infiltrating lymphocytes (TILs) — immune cells found within tumors — are another area of active research. Higher levels of TILs in a TNBC tumor appear to be associated with better outcomes and lower recurrence risk, particularly in early-stage disease. Clinical trials may use TIL levels to guide treatment decisions, leading to immunotherapies and potentially sparing some patients from intensive chemotherapy.
TNBC vaccines are also generating significant interest. Early-phase clinical trials are underway to develop vaccines that train the immune system to target proteins produced by TNBC tumors. We’re years away from broad use, but it’s a genuinely hopeful direction.
With a major focus on new treatments for people dealing with TNBC, we’re finally seeing more cures with fewer side effects — as well as new options for people who develop recurrence after traditional therapies.
If you have TNBC, be sure to ask your doctor about clinical trials. With so much research actively underway, a trial may open doors to treatments not yet available through standard care. Less than one in 20 cancer patients currently participate in clinical trials — but for TNBC especially, trials provide future hope.
A TNBC diagnosis is serious, but it's not a death sentence. Know your body, get screened, push for genetic testing, and don’t be afraid to ask hard questions. For more information about TNBC and community support for all things related to breast cancer, visit Breastcancer.org.
Dr. Marisa C. Weiss is the founder and Chief Medical Officer of Breastcancer.org, the leading patient-centered resource for breast health and breast cancer. A quadruple board-certified physician and breast cancer survivor, she currently serves as director of breast radiation oncology and director of breast health at Main Line Health.
